I think ß-secretase inhibitors therapies will face similar challenges to those seen with y-secretase (because the enzyme has many substrates* and a wide substrate binding domain) I'd expect serious off-target tox.
*like neuregulin-1, which is involved in myelination and y-secretase inhibitors have in fact shown AE on myelin in animal models.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.